sever
acut
respiratori
syndrom
sar
emerg
guandong
provinc
southern
china
new
infecti
respiratori
diseas
character
influenzalik
symptom
sign
high
mortal
rate
ksiazek
et
al
peiri
et
al
novel
coronaviru
term
sarscov
identifi
etiolog
agent
drosten
et
al
drosten
et
al
world
health
organ
report
sar
case
novemb
juli
approxim
patient
die
http
subsequ
outbreak
includ
two
laboratori
event
occur
rapidli
contain
outbreak
demonstr
need
strategi
treat
sporad
case
sar
diseas
includ
econom
lethal
rodent
model
would
simul
human
sar
diseas
studi
molecular
evolut
sarscov
suggest
viru
emerg
nonhuman
sourc
although
natur
reservoir
viru
posit
identifi
current
hypothesi
horsesho
bat
main
natur
reservoir
sarscovlik
virus
hon
et
al
li
et
al
number
sarscovlik
virus
isol
bat
although
full
lineag
ancestor
sarscov
remain
uncharacter
hon
et
al
viru
transmiss
human
may
occur
civet
cat
infect
bat
trade
chines
wet
market
sever
sarscov
infect
human
character
diffus
alveolar
damag
spars
inflammatori
infiltr
chen
subbarao
frank
et
al
nichol
et
al
hyalin
membran
format
hallmark
sarscov
lung
damag
human
hsiao
et
al
addit
hyalin
membran
format
sever
sar
case
find
could
includ
serou
fibrin
hemorrhag
inflamm
pulmonari
alveoli
capillari
engorg
includ
microthrombosi
capillari
lang
et
al
pulmonari
alveoli
thicken
interstiti
mononuclear
inflammatori
infiltr
desquam
pneumocyt
detect
along
fibrinoid
materi
erythrocyt
alveolar
space
lang
et
al
cell
type
respiratori
tract
sarscov
antigen
detect
includ
follow
alveolar
epitheli
cell
primarili
type
ii
pneumocyt
bronchial
epitheli
cell
alveolar
macrophag
ding
et
al
ye
et
al
cell
type
angiotensinconvert
enzym
identifi
one
receptor
sarscov
bind
order
taken
host
cell
li
et
al
number
anim
speci
propos
model
sar
infect
human
includ
macaqu
marmoset
greenough
et
al
mice
glass
et
al
robert
et
al
golden
syrian
hamster
rat
nagata
et
al
cat
martina
et
al
van
den
brand
et
al
ferret
chu
et
al
martina
et
al
subbarao
robert
van
den
brand
et
al
util
variou
anim
model
extens
review
briefli
nonprim
model
exactli
model
lung
patholog
found
human
exampl
hyalin
membran
format
seen
rare
detect
rodent
model
fever
also
detect
nevertheless
rodent
model
may
util
model
low
expens
eas
handl
defin
genet
possibl
largescal
statist
signific
studi
advantag
lethal
rodent
model
would
extrem
valuabl
antivir
drug
test
amount
experiment
compound
avail
evalu
anim
often
limit
sinc
earli
sar
outbreak
concert
effort
mani
laboratori
evalu
vaccin
du
et
al
develop
clinic
approv
drug
efficaci
sarscov
rapidli
provid
treatment
sar
infect
human
tong
b
date
approv
agent
treat
sarscov
agent
reach
human
clinic
trial
wong
yuen
due
lack
anim
model
test
among
reason
ribavirin
use
treat
sar
infect
efficaci
question
may
exacerb
diseas
mice
barnard
et
al
human
stockman
bellami
garner
wu
other
recent
review
state
drug
discoveri
sarscov
antivir
agent
pyrc
berkhout
van
der
hoek
stockman
bellami
garner
tong
wu
et
al
yeung
meanwel
current
studi
report
pathogenesi
genet
chang
sarscov
strain
call
adapt
sarscov
urbani
serial
passag
caus
lethal
pulmonari
syndrom
mice
use
multipl
drug
purport
antivir
activ
util
new
strain
model
viru
evalu
drug
cell
cultur
mice
shown
urbani
strain
sarscov
lethal
balbc
mice
serial
passag
time
balbc
mice
interv
result
highli
lethal
strain
design
viru
caus
sever
sign
ill
balbc
mice
includ
ruffl
fur
lethargi
within
day
death
day
anoth
lethal
mouseadapt
strain
design
robert
et
al
test
parallel
comparison
mouseadapt
strain
caus
substanti
weight
loss
produc
high
viru
titer
lung
infect
mice
tabl
contrast
sarscov
strain
urbaniinfect
mice
signific
weight
loss
compar
uninfect
control
although
moder
viru
titer
lung
day
postviru
exposur
shown
previous
barnard
et
al
b
lung
viru
titer
day
postviru
inocul
dpi
higher
mice
mice
lung
titer
appear
depend
level
viru
inoculum
differ
depend
viru
strain
viru
viru
persist
lung
day
urbani
strain
detect
limit
day
nt
b
urbani
b
uninfect
none
b
b
b
compar
correspond
dilut
test
due
earli
death
mice
viru
concentr
b
averag
contain
one
valu
limit
detect
infect
result
mice
lose
initi
weight
mice
die
depend
infecti
dose
tabl
nearli
mice
lost
initi
weight
infect
ccid
tabl
confirm
result
observ
mice
robert
et
al
howev
strain
kill
mice
strain
regardless
inoculum
use
tabl
viru
lethal
concentr
low
ccid
per
mous
replic
experi
result
similar
tabl
except
mice
receiv
ccid
die
tabl
howev
mice
die
mean
day
death
mdd
day
compar
mdd
correspond
group
tabl
overal
death
mice
infect
significantli
greater
p
b
mice
fig
recoveri
sever
ill
like
mice
mice
lethal
lower
infecti
dose
averag
ld
ccid
per
mous
data
uniqu
special
provis
anim
euthan
sever
ill
allow
die
recov
spontan
anim
experi
repeat
compar
mice
mice
tabl
older
mice
infect
lost
weight
dpi
correspond
mice
mdd
day
later
mice
mortal
mice
high
mouseadapt
viru
strain
use
ccid
inocula
howev
mice
receiv
inoculum
die
correspond
mice
die
mice
die
urbani
infect
interestingli
one
separ
age
experi
mice
week
old
die
ccid
infect
mice
die
data
shown
support
notion
sarscov
lethal
older
host
viru
nine
mutat
one
affect
two
read
frame
result
chang
amino
acid
residu
compar
wildtyp
urbani
four
mutat
occur
spike
protein
region
fig
put
ga
mutat
observ
base
pair
replic
found
rna
infect
mous
lung
mutat
compar
lethal
strain
robert
et
al
reveal
interest
similar
differ
mutat
spectra
associ
mous
adapt
young
balbc
mice
fig
structur
gene
mutat
spike
region
conserv
strain
mutat
similar
locat
lethal
strain
replicas
gene
mutat
locat
near
mutat
found
strain
lethal
strain
mutat
mouseadapt
strain
sarscov
elicit
express
cytokin
chemokin
rant
lung
mice
day
infect
measur
multiplex
elisa
assay
fig
level
gmcsf
minimum
detect
level
test
group
pgml
lung
homogen
low
level
observ
mouseadapt
strain
detect
urbani
strain
two
mice
show
low
cytokin
respons
exclud
cytokin
analysi
also
littl
viru
detect
lung
viru
stimul
significantli
rant
compar
urbani
p
b
viru
caus
significantli
greater
respons
urbani
p
b
significantli
higher
respons
compar
wildtyp
urbani
strain
observ
mouseadapt
strain
p
b
p
b
respect
mice
express
mice
infect
level
use
experi
mice
die
mice
die
show
correl
concentr
lung
mortal
three
lung
sampl
viru
control
evalu
patholog
chang
day
inocul
board
certifi
veterinari
pathologist
fig
lung
mice
inocul
urbani
strain
sarscov
show
signific
chang
shaminfect
control
show
mark
chang
except
scatter
dens
granuloma
one
three
lung
three
lung
show
small
number
foami
macrophag
small
number
neutrophil
alveolar
septa
seen
two
three
lung
one
lung
rare
individu
bronchiolar
line
cell
swollen
hypereosinophil
degener
patholog
chang
observ
two
three
lung
one
moder
number
neutrophil
edema
fluid
surround
sever
larg
vessel
rare
granuloma
contain
refractil
central
fragment
foreign
materi
replac
group
alveoli
anoth
lung
show
small
number
alveolar
macrophag
throughout
airspac
gener
lung
infect
show
acut
subacut
alveol
perivascular
edema
section
fig
differ
two
mouseadapt
strain
minim
hyalin
membran
format
occur
human
sar
patient
robert
et
al
observ
demonstr
util
lethal
mous
model
antivir
drug
test
evalu
known
antivir
agent
ribavirin
antivir
nucleosid
analog
sidwel
et
al
poli
poli
c
u
synthet
dsrna
polym
induc
interferon
product
barnard
et
al
carter
et
al
gowen
et
al
also
evalu
novel
drug
dipeptidyl
glutaminyl
fluoromethylketon
proteas
inhibitor
zhang
et
al
uda
lectin
imped
viral
fusion
egress
keyaert
et
al
mgkgday
afford
mice
complet
protect
death
reduc
viru
titer
lung
significantli
reduc
lung
score
weight
loss
tabl
uda
treatment
mgkgday
result
protect
death
day
infect
tabl
reduct
lung
viru
titer
replic
studi
show
protect
measur
tabl
viru
lung
titer
mice
treat
ribavirin
differ
detect
control
mice
dpi
dpi
titer
ribavirintr
mice
higher
detect
control
group
suggest
ribavirin
prolong
lung
infect
although
differ
statist
signific
tabl
gross
patholog
lung
score
day
reveal
substanti
lung
discolor
ribavirintr
mice
mdd
mice
treat
ribavirin
reduc
tabl
survivor
curv
statist
similar
pss
control
fig
second
experi
viru
titer
lower
control
ribavirintr
mice
day
tabl
group
also
die
pi
data
shown
concentr
lung
dpi
significantli
lower
p
b
mice
receiv
ribavirin
treatment
slightli
lower
uda
compar
control
tabl
mice
show
differ
compar
control
uninfect
control
group
level
pgml
could
result
stress
induc
handl
mice
daili
weight
twice
daili
treatment
therefor
pgml
consid
baselin
concentr
studi
histopatholog
mice
vari
antivir
treatment
show
neutrophil
infiltr
degener
cell
tabl
lesion
observ
board
certifi
pathologist
summar
tabular
form
lesion
observ
includ
lung
mice
treat
proteas
inhibitor
cremaphor
solvent
control
appear
less
overal
lesion
dpi
lung
mice
treatment
group
ribavirintr
lung
fewer
overal
lesion
group
dpi
macrophag
infiltr
lymphocyt
infiltr
edema
detect
infect
lung
experi
hyalin
membran
format
observ
histolog
chang
similar
treat
group
untreat
control
group
tabl
strain
test
vitro
sensit
multipl
antivir
compound
compound
chosen
base
mode
action
purport
activ
previou
literatur
cell
treat
multipl
concentr
compound
infect
viru
effect
concentr
ec
cytotox
concentr
ic
select
index
si
compound
calcul
tabl
compound
high
select
index
consid
activ
antivir
activ
drug
similar
compound
urbani
strain
p
n
consensu
kumaki
et
al
shown
highli
activ
effect
concentr
strain
si
valu
ribavirin
promazin
antipsychot
drug
calpain
inhibitor
vi
barnard
et
al
show
appreci
activ
cytotox
concentr
tabl
zhang
et
al
uda
moder
activ
calpain
inhibitor
iv
barnard
et
al
slightli
activ
sarscov
urbani
strain
effect
concentr
si
valu
respect
strain
appear
less
sensit
calpain
inhibitor
iv
strain
urbani
although
differ
statist
signific
develop
new
mouseadapt
strain
call
caus
increas
morbid
mortal
balbc
mice
parent
urbani
strain
strain
deriv
urbani
strain
sarscov
serial
passag
balbc
mice
mice
infect
strain
less
like
surviv
sarscov
infect
urbaniinfect
mice
strain
appear
less
lethal
current
studi
shown
robert
et
al
howev
studi
previous
report
death
base
weight
loss
weight
loss
equat
mortal
current
work
result
close
similar
previou
report
tabl
prior
find
inoculum
ccid
per
mous
subleth
robert
et
al
confirm
current
work
reduc
lethal
strain
current
experi
may
also
attribut
use
mice
rather
mice
current
studi
mice
much
less
suscept
mice
tabl
sarscov
known
fatal
age
patient
younger
patient
chen
subbarao
agerel
suscept
sarscov
mice
shown
previous
versu
mice
nagata
et
al
mice
robert
et
al
mice
rockx
et
al
lethal
viru
younger
mice
advantag
use
conveni
model
evalu
potenti
antivir
treatment
genom
contain
nine
mutat
compar
parent
urbani
strain
result
amino
acid
residu
chang
sinc
bp
affect
two
read
frame
although
strain
develop
independ
genom
share
mutat
previous
creat
mouseadapt
strain
fig
spike
mutat
common
lethal
strain
within
receptorbind
motif
robert
et
al
mutat
shown
enhanc
infect
recombin
virus
mice
becker
et
al
presum
provid
favor
interact
receptor
dock
entri
strain
three
mutat
spike
region
present
suggest
increas
virul
observ
potenti
may
due
bind
properti
moreov
contact
interfac
residu
site
engag
receptor
passag
civet
strain
human
airway
epitheli
cell
select
similar
chang
posit
shown
enhanc
interact
receptor
separ
work
mutat
seen
third
mouseadapt
strain
amino
acid
residu
mutat
frieman
et
al
public
prepar
interestingli
alter
heptad
repeat
element
could
promot
fusion
entri
host
rang
expans
mcroy
baric
mutat
outsid
spike
region
also
appear
import
mutat
glycoprotein
gene
near
mutat
associ
increas
product
viru
particl
infect
cell
presum
promot
effici
assembl
releas
although
exact
mechan
unknown
pacciarini
et
al
mutat
locat
near
mutat
like
confer
similar
phenotyp
differ
presum
increas
virul
lethal
strain
mutat
although
known
confer
similar
chang
protein
structur
fact
independ
select
result
similar
mutat
profil
target
gene
support
role
increas
replic
andor
pathogenesi
elucid
effect
specif
mutat
may
key
understand
genotyp
variat
lead
lethal
phenotyp
sarscov
coronavirus
gener
knowledg
could
allow
rapid
synthesi
chimer
virus
use
evalu
develop
effect
antivir
treatment
multipl
cytokin
chemokin
express
lung
balbc
mice
dpi
infect
mouseadapt
sarscov
significantli
higher
found
lung
mice
infect
urbani
strain
sarscov
fig
strongli
express
mice
mice
observ
human
sar
patient
chen
subbarao
one
human
studi
determin
indic
high
risk
death
jiang
et
al
therefor
like
good
earli
indic
diseas
outcom
mice
contrast
cytokin
rant
elev
group
group
sinc
mice
lower
mortal
mice
rant
may
good
indic
diseas
outcom
compar
mous
cytokin
profil
detect
human
sar
patient
major
human
studi
show
profil
seen
mice
chen
subbarao
hsueh
et
al
zhu
tabl
contrast
elev
mous
lung
human
lung
serum
three
five
studi
review
show
elev
human
patient
rant
elev
mous
lung
human
sera
howev
uninfect
control
elev
rant
level
mice
well
respons
consid
import
detect
lethal
infect
mous
lung
human
lung
nevertheless
find
consid
consist
human
data
sinc
level
mice
low
found
human
serum
studi
other
two
mouseadapt
sarscov
strain
studi
result
similar
cytokin
profil
fig
level
particular
interest
increas
correspond
directli
increas
mortal
respect
tabl
cytokin
respons
sarscov
infect
lethallyinfect
mice
compar
human
sar
diseas
lung
lethallyinfect
mice
human
lung
number
studi
human
serum
b
number
studi
review
c
separ
studi
current
press
experiment
group
mice
infect
wildtyp
urbani
strain
show
sign
diseas
death
detect
lung
mice
express
high
level
one
replic
studi
mice
die
averag
level
lung
homogen
group
pg
ml
one
mous
lower
pgml
correspond
group
studi
recoveri
sever
ill
mice
averag
concentr
pgml
sampl
higher
pgml
similarli
one
clinic
studi
found
patient
poorest
outcom
also
high
level
secret
cell
current
work
infect
mice
receiv
pss
cremaphor
group
show
higher
concentr
ribavirin
uda
group
tabl
lower
concentr
dpi
coincid
treatment
afford
least
protect
death
surviv
studi
tabl
role
sarscov
infect
merit
investig
critic
bcell
matur
acutephas
respons
kopf
et
al
critic
coordin
immun
respons
gowen
et
al
convers
studi
report
hegd
pahn
smolahess
suggest
also
immunosuppress
properti
howev
high
express
may
exacerb
diseas
sar
patient
damag
lung
seem
primarili
viral
destruct
alveolar
bronchial
epitheli
cell
macrophag
chen
subbarao
howev
elev
level
concomit
lung
damag
continu
even
peak
viru
product
suggest
contribut
diseas
progress
furthermor
sar
patient
studi
show
alter
liver
function
leucopenia
lymphopenia
thrombocytopenia
subsequ
respiratori
distress
syndrom
suggest
inflammatori
damag
result
sarscov
infect
peiri
et
al
studi
virus
also
suggest
excess
product
may
exacerb
diseas
exampl
studi
herp
simplex
viru
hsv
suggest
exuber
product
neonat
may
explain
sepsi
syndrom
common
hsv
infect
neonat
adult
kurt
jone
et
al
studi
phleboviru
infect
also
propos
contribut
pathogenesi
gowen
et
al
regardless
causeeffect
relationship
found
strongli
express
lung
infect
mouseadapt
sarscov
viru
may
effect
predictor
diseas
outcom
histopatholog
sar
difficult
distinguish
lesion
observ
sar
found
mani
infect
main
distinguish
histopatholog
factor
human
sar
diseas
consolid
edema
hyalin
membran
format
guo
et
al
also
inflammatori
infiltr
usual
compos
mostli
macrophag
lymphocyt
disproportion
low
number
respect
alveolar
damag
sometim
absent
chen
subbarao
cheung
et
al
guo
et
al
current
studi
lung
infect
mouseadapt
strain
sarscov
show
acut
subacut
alveol
perivascular
edema
section
mice
lung
slight
moder
neutrophil
macrophag
infiltr
lymphocyt
observ
erythrocyt
infiltr
fibrin
materi
observ
experi
shown
hyalin
membran
form
mous
lung
sinc
lung
patholog
differ
human
diseas
sinc
mice
group
die
infect
similar
patholog
treat
mice
surviv
infect
tabl
submit
histopatholog
import
marker
sar
model
sar
infect
multipl
tissu
human
includ
spleen
intestin
kidney
liver
adren
parathyroid
pituitari
cerebrum
pancrea
neuron
cn
chen
subbarao
guo
et
al
infecti
viru
consist
found
lung
snout
inocul
mice
day
postinocul
rare
seen
serum
viru
recov
kidney
brain
spleen
intestin
liver
heart
mice
limit
detect
log
ccid
kidney
log
ccid
brain
spleen
heart
log
ccid
liver
intestin
data
shown
robert
et
al
report
low
titer
infecti
viru
found
lung
brain
spleen
liver
mice
infect
ribavirin
uda
treatment
select
assess
new
strain
sarscov
model
vivo
evalu
potenti
antivir
drug
drug
chosen
repres
varieti
mode
action
ribavirin
known
antivir
compound
sidwel
et
al
multipl
mode
action
stem
inhibit
inosin
monophosph
dehydrogenas
impdh
lead
depress
intracellular
gtp
level
streeter
et
al
previous
found
mous
viru
lung
replic
model
sarscov
ribavirin
extend
time
viru
could
detect
lung
mice
barnard
et
al
also
observ
one
trial
current
studi
tabl
prolong
high
lung
titer
observ
suggest
ribavirin
may
contribut
pathogenesi
sarscov
prolong
andor
enhanc
viral
replic
lung
allow
continu
stimul
inflammatori
respons
may
contribut
pathogenesi
perlman
dandekar
also
ribavirin
known
somewhat
toxic
caus
hemolyt
anemia
advers
side
effect
wong
yuen
ribavirin
would
presum
exacerb
diseas
concomit
antivir
effect
interestingli
exacerb
viral
diseas
ribavirin
also
shown
west
nile
viru
result
increas
mortal
hamster
possibl
human
patient
chower
et
al
contrast
second
experi
current
work
show
significantli
decreas
concentr
dpi
somewhat
decreas
viru
titer
ribavirintr
anim
dpi
suggest
effect
ribavirin
mice
tabl
reduct
ribavirin
interest
light
previou
report
ribavirin
inhibit
product
respiratori
epithelia
cell
infect
rsv
viru
jiang
kunimoto
patel
endotheli
cell
infect
dengu
viru
huang
et
al
howev
reduc
ribavirin
activ
tcell
hultgren
et
al
ribavirin
treatment
reduc
sarscov
viral
load
human
sar
patient
ribavirin
shown
effect
sar
human
systemat
review
comprehens
summari
treatment
use
sar
patient
found
studi
ribavirin
inconclus
four
show
possibl
harm
stockman
bellami
garner
howev
review
state
ribavirin
treatment
combin
proteas
inhibitor
could
use
clinic
although
random
control
trial
still
need
wong
yuen
anoth
studi
show
synergi
ribavirin
combin
vitro
morgenstern
et
al
addit
research
requir
draw
certain
conclus
ribavirin
mice
includ
agerel
studi
drug
combin
experi
use
lethal
viru
model
poli
c
u
synthet
dsrna
polym
stimul
product
interferon
carter
et
al
gowen
et
al
shown
effect
vivo
multipl
virus
includ
coxsacki
viru
padalko
et
al
venezuelan
equin
enceph
vee
viru
juland
et
al
punta
toro
viru
sidwel
et
al
modoc
viru
leyssen
et
al
duck
hepat
b
viru
niu
et
al
banzi
viru
pinto
morahan
brinton
herp
simplex
type
viru
pinto
morahan
brinton
pichind
viru
smee
et
al
viru
replic
model
mgkg
previous
found
afford
protect
sarscov
replic
lung
barnard
et
al
sarscov
known
sensit
type
interferon
cinatl
et
al
stroher
et
al
normal
presenc
doublestrand
rna
ssrna
viral
infect
ifn
synthes
secret
infect
cell
stimul
express
potent
antivir
protein
sadler
william
samuel
howev
ifn
pathway
block
cell
infect
sarscov
frieman
heis
baric
thu
make
host
suscept
infect
believ
exogen
stimul
ifn
pathway
overcom
evas
viru
sens
signal
pathway
furthermor
kuri
et
al
suggest
prime
small
amount
ifn
help
cell
restor
normal
ifn
respons
sarscov
current
studi
appear
affect
viru
replic
initi
led
rapid
declin
viru
lung
compar
untreat
anim
dpi
tabl
studi
show
protect
death
gross
damag
lung
presenc
lethal
sarscov
sting
nettl
lectin
urtica
doica
agglutinin
uda
nacetyl
glucosaminespecif
lectin
report
efficaci
hiv
de
clercq
recent
uda
report
inhibit
coronavirus
vitro
select
van
der
meer
et
al
keyaert
et
al
show
uda
potent
select
inhibitor
sarscov
strain
plant
lectin
like
uda
probabl
target
viral
attach
fusion
exocytosi
egress
viru
cell
balzarini
van
der
meer
et
al
keyaert
et
al
reduct
lung
dpi
along
surviv
mice
studi
provid
evid
support
investig
uda
treatment
regimen
potenti
antivir
therapi
zhang
et
al
report
design
synthesi
sarscov
proteas
inhibitor
zvalamido
acid
dimethylamid
chemic
formula
c
h
fn
molecular
weight
shown
inhibit
replic
sarscov
strain
vero
caco
cell
current
studi
activ
cell
cultur
urbani
strain
sarscov
tabl
efficaci
prevent
death
reduc
diseas
sign
measur
balbc
mice
tabl
sinc
rel
insolubl
lack
activ
like
bioavail
anim
uninfect
mice
toxic
replic
trial
use
dmso
solvent
yield
similar
result
cremaphor
data
shown
nevertheless
base
vitro
result
compound
may
foundat
effect
antivir
proteas
prodrug
develop
make
solubl
bioavail
vitro
sensit
antivir
compound
strain
similar
strain
urbani
p
n
two
strain
test
parallel
multipl
compound
vitro
data
confirm
recent
find
barnard
et
al
barnard
et
al
promazin
antipsychot
drug
ribavirin
nucleosid
analog
effect
sarscov
vitro
find
support
prior
find
activ
vitro
sarscov
urbani
kumaki
et
al
proteas
inhibitor
activ
vitro
shown
previous
zhang
et
al
current
vitro
result
show
mark
activ
calpain
inhibitor
vi
slight
moder
activ
calpain
inhibitor
iv
previou
report
show
greater
antivir
activ
calpain
inhibitor
vi
calpain
inhibitor
iv
barnard
et
al
differ
attribut
greater
cell
sensit
drug
toxic
previou
work
inoculum
variat
studi
stronger
viru
replic
mammalian
cell
cultur
current
studi
uda
found
moder
activ
antivir
select
si
previou
work
keyaert
et
al
therefor
strain
shown
effect
evalu
antivir
compound
vitro
use
microscop
cytopath
effect
neutral
red
assay
viru
yield
reduct
test
use
strain
variou
vitro
assay
allow
detect
highli
activ
compound
variou
inact
compound
facilit
futur
analysi
antivir
compound
sinc
screen
vitro
strain
test
vivo
strain
conclus
new
mouseadapt
strain
sarscov
highli
virul
balbc
mice
week
old
even
infecti
dose
low
ccid
per
mous
infect
caus
sign
diseas
strong
immunolog
respons
lung
patholog
infect
larg
simul
human
diseas
except
hyalin
membran
format
detect
lung
infecti
viru
found
tissu
outsid
respiratori
tract
characterist
human
infect
chen
subbarao
mutat
viru
consist
seen
anoth
mouseadapt
strain
may
use
identifi
genotyp
marker
lethal
strain
propag
well
cell
cultur
shown
suitabl
vitro
screen
potenti
antivir
compound
sarscov
strain
use
effect
vivo
model
evalu
sarscov
therapi
show
pretreat
activ
lethal
sarscov
infect
uda
may
antivir
effect
well
new
model
facilit
identif
valuabl
antivir
compound
sarscov
futur
emerg
pathogen
relat
sarscov
femal
balbc
mice
obtain
charl
river
laboratori
wilmington
maintain
wayn
lab
blox
tap
water
ad
libitum
quarantin
h
prior
use
cell
use
atcc
atcc
vero
atcc
maintain
mem
supplement
fetal
bovin
serum
fb
antibiot
viru
titer
test
mem
fb
gentamicin
use
ribavirin
provid
icn
pharmaceut
costa
mesa
ca
calpain
inhibitor
iv
calpain
inhibitor
vi
obtain
calbiochem
san
diego
ca
interferon
lot
kindli
provid
intermun
inc
brisban
ca
solut
held
frozen
test
hemispherx
biopharma
inc
obtain
niaid
antivir
substanc
program
promazin
hcl
obtain
sigma
chemic
corpor
st
loui
mo
obtain
epicept
corpor
san
diego
ca
niaid
antivir
substanc
program
sting
nettl
lectin
uda
obtain
ey
laboratori
inc
san
mateo
ca
compound
suspend
dmso
purifi
water
mm
dilut
minim
essenti
medium
mem
need
vitro
assay
compound
vivo
assay
dilut
salin
except
proteas
inhibitor
dilut
cremaphor
vehicl
cremaphor
ethanol
purifi
water
strain
sarscov
mouseadapt
viru
kindli
provid
dr
kanta
subbarao
nation
institut
health
niaid
design
vero
cell
cytokin
lung
patholog
viru
infect
balbc
mice
mous
lung
homogen
contain
viru
filter
subcultur
vero
atcc
cell
cultur
day
cell
cultur
homogen
sonic
frozen
vivo
work
viru
subcultur
cell
mem
fb
mm
sodium
pyruv
mm
nonessenti
amino
acid
incub
cell
cultur
homogen
sonic
centrifug
clarifi
solut
aliquot
held
frozen
subcultur
stock
verifi
pcr
use
primer
flank
characterist
mutat
sever
acut
respiratori
syndrom
coronaviru
sarscov
strain
urbani
obtain
center
diseas
control
prevent
cdc
atlanta
ga
routin
passag
cell
three
balbc
mice
anesthet
ketaminexylazin
mixtur
approxim
mgkg
mgkg
respect
infect
sarscov
urbani
viru
solut
nasal
inhal
three
day
infect
mice
euthan
lung
remov
homogen
ml
mem
fb
homogen
test
viru
titer
cpe
endpoint
dilut
assay
reinfect
subsequ
group
mice
infect
step
continu
passag
passag
homogen
dilut
addit
passag
without
dilut
lung
homogen
group
determin
valid
control
mice
demonstr
notabl
effect
inhal
uninfect
lung
tissu
one
interim
passag
plaqu
purifi
passag
ceas
increas
viru
titer
lung
sign
ill
observ
infect
anim
lung
homogen
passag
mice
filter
subcultur
cell
dilut
plate
isol
singl
plaqu
plaqu
purif
cell
repeat
three
time
four
isol
plaqu
subcultur
cell
compar
infect
balbc
mice
virul
isol
select
aliquot
viru
stock
incub
mem
medium
day
demonstr
growth
extran
bacteria
fungi
rna
isol
viru
stock
use
rneasi
kit
qiagen
alameda
ca
test
qrtpcr
two
primer
pair
verifi
presenc
sarscov
sequenc
access
presenc
sarscov
antigen
viru
stock
also
demonstr
use
sarscov
ag
detect
kit
wantai
inc
china
new
viru
stock
design
sarscov
usu
strain
use
subsequ
studi
hereaft
refer
sequenc
analysi
perform
univers
north
carolina
rna
purifi
cell
lysat
cell
infect
sarscov
use
rneasi
kit
qiagen
alameda
ca
follow
firststrand
cdna
synthesi
revers
transcript
use
superscript
ii
invitrogen
carlsbad
ca
per
manufactur
protocol
revers
transcript
perform
initi
incub
min
cool
ice
follow
incub
denatur
two
microlit
cdna
reaction
amplifi
pcr
use
accuprim
high
fidel
taq
polymeras
invitrogen
carlsbad
ca
fifteen
pair
primer
use
gener
overlap
pcr
product
space
everi
kb
gener
dna
fragment
bp
overlap
end
amplif
product
visual
agaros
gel
purifi
use
qiaquick
gel
extract
kit
qiagen
alameda
ca
pcr
product
sequenc
forward
revers
direct
primer
space
everi
bp
along
genom
autom
sequenc
perform
util
bigdy
termin
version
cycl
sequenc
kit
appli
biosystem
foster
citi
ca
per
manufactur
instruct
abi
prism
dna
analyz
appli
biosystem
sequenc
assembl
analyz
vector
nti
auto
assembl
dna
sequenc
assembl
softwar
abi
prism
appli
biosystem
mutat
identifi
comparison
sarscov
publish
sequenc
urbani
access
independ
rtpcr
reaction
run
subsequ
rtpcr
product
sequenc
region
contain
put
mutat
confirm
mutat
mice
week
old
g
separ
group
mice
sacrific
day
postinfect
mice
weight
surviv
data
mice
anesthet
ml
intraperiton
inject
ketamin
mgkg
xylazin
mg
kg
infect
intranas
suspens
viru
mice
inocul
approxim
ccid
plaqu
assay
perform
cell
actual
inocula
infect
show
viru
titer
equal
higher
correspond
titer
replic
experi
wildtyp
control
comparison
mice
inocul
approxim
ccid
urbani
sarscov
strain
group
mice
sham
infect
mem
neg
control
group
surviv
mice
weigh
individu
nearest
g
day
observ
daili
death
anim
held
death
natur
occur
dpi
three
day
dpi
five
survivor
group
euthan
lung
remov
lung
dilut
mem
fb
homogen
held
viru
titer
test
lung
homogen
later
thaw
serial
dilut
mem
fb
triplic
plate
obtain
ccid
valu
endpoint
dilut
method
describ
viru
yield
reduct
assay
mean
day
death
mdd
calcul
use
mice
die
exclud
survivor
studi
repeat
mice
g
mice
tabl
anoth
studi
perform
inoculum
balbc
mice
variou
age
determin
agedepend
suscept
lethal
infect
group
mice
g
inocul
intranas
three
viru
strain
suspend
mem
solut
control
mock
infect
salin
inocula
ccid
per
mous
log
ccid
urbani
day
postviru
exposur
five
surviv
mice
euthan
lung
harvest
remain
mice
held
measur
weight
loss
death
lung
section
save
histopatholog
formalin
solut
remain
lung
section
dilut
mem
solut
homogen
held
frozen
sampl
test
cytokin
gmcsf
chemokin
rant
use
mous
cytokin
array
screen
quansi
bioscienc
logan
ut
quantit
elisabas
test
multipl
distinct
captur
antibodi
absorb
well
plate
defin
array
cytokin
quantifi
rel
luminesc
spot
array
valu
pgml
calcul
use
concurrentlyrun
quansi
standard
curv
softwar
version
one
replic
rant
valu
exceed
standard
curv
rang
estim
extrapol
fig
two
mice
abnorm
low
cytokin
exclud
outlier
littl
viru
detect
lung
cytokin
result
mice
two
experi
combin
averag
standard
deviat
kruskalw
analysi
varianc
follow
dunn
multipl
comparison
test
compar
urbaniinfect
mice
group
anim
infect
describ
cytokin
assay
day
lung
sham
control
mice
expos
ccid
urbani
formalinfix
three
lung
group
section
stain
h
e
stain
evalu
board
certifi
veterinari
pathologist
histopatholog
chang
group
mice
g
inocul
contain
ccid
viru
rout
group
mice
administ
follow
drug
intraperiton
ip
rout
ribavirin
mgkg
twice
day
h
apart
day
begin
h
prior
exposur
viru
mgkg
four
treatment
h
apart
begin
h
viru
exposur
physiolog
salin
solut
pss
placebo
use
dose
regimen
describ
ribavirin
separ
studi
mice
treat
uda
mgkgday
use
treatment
regimen
describ
ribavirin
mice
treat
mgkgday
proteas
suspend
cremaphor
administ
bid
day
begin
time
infect
mice
toxic
control
treat
pss
cremaphor
diluent
use
treatment
regimen
describ
without
viru
exposur
mice
observ
daili
group
weight
taken
period
throughout
test
period
averag
weight
loss
calcul
dpi
signific
treatment
evalu
oneway
analysi
varianc
follow
newmankeul
multipl
comparison
test
compound
toxic
uninfect
mice
evalu
term
weight
chang
advers
event
drug
toxic
observ
studi
day
postinfect
three
five
surviv
mice
treatment
group
sacrif
remain
mice
held
observ
death
day
postviru
exposur
day
uda
anim
lost
greater
initi
bodi
weight
experi
human
euthan
day
euthanasia
design
day
death
lung
sacrif
mice
observ
gross
patholog
discolor
assign
score
rang
normal
appear
lung
maxim
plum
color
lung
mous
lung
sampl
test
group
pool
homogen
mem
solut
assay
duplic
infecti
viru
use
method
describ
viru
yield
assay
use
triplic
well
cell
procedur
repeat
mice
histopatholog
viru
titer
lung
tabl
multipl
tissu
dpi
lung
section
place
formalin
examin
histopatholog
describ
remain
lung
portion
homogen
individu
ml
mem
fb
held
frozen
sampl
thaw
mix
test
level
use
ebiosci
san
diego
ca
elisa
kit
per
manufactur
instruct
sampl
size
three
per
treatment
group
histopatholog
four
five
viru
titer
depend
number
survivor
remain
valu
pgg
lung
convert
pgml
correspond
dilut
use
initi
untreat
mice
fig
low
outlier
salin
day
pgml
includ
result
exclud
statist
analysi
level
treat
group
compar
untreat
control
anova
newmankeul
pairwis
comparison
individu
tissu
harvest
separ
steril
instrument
ensur
tissu
isol
lung
necropsi
tissu
homogen
titer
perform
describ
lung
antivir
activ
test
compound
evalu
use
mouseadapt
viru
strain
vitro
model
compar
strain
urbani
run
concurr
antivir
activ
measur
inhibit
virusinduc
cytopath
effect
cpe
sidwel
huffman
neutral
red
nr
dye
uptak
mcmanu
also
viru
yield
reduct
assay
atcc
crl
cell
grown
mem
fetal
bovin
serum
fb
seed
plate
concentr
cell
per
well
grown
overnight
co
test
compound
dissolv
dmso
water
serial
dilut
mem
halflog
dilut
triplic
well
test
well
infect
multipl
infect
moi
less
ccid
per
cell
suffici
caus
near
complet
cytopath
effect
cpe
day
log
ccid
per
well
urbani
log
ccid
per
well
test
medium
mem
fb
gentamicin
toxic
compound
assay
duplic
well
without
viru
plate
incub
day
well
read
microscop
cpe
cell
incub
nr
dye
h
free
dye
remov
well
uptaken
dye
elut
ethanol
sorensen
citrat
buffer
min
absorb
measur
describ
finter
opsi
mr
micropl
reader
dynex
chantilli
va
nm
absorb
valu
visual
cpe
express
percentag
cell
control
untreat
viru
control
adjust
toxic
effect
concentr
ec
inhibitori
concentr
cytotox
ic
valu
calcul
regress
analysi
viru
yield
reduct
assay
perform
use
cell
cultur
infecti
dose
ccid
assay
essenti
describ
previous
smee
et
al
briefli
supernat
well
serial
dilut
triplic
well
plate
contain
cell
plate
incub
day
check
virusinduc
cpe
quantit
viru
yield
titer
end
point
method
reed
muench
ec
valu
calcul
use
linear
regress
estim
concentr
necessari
inhibit
viru
yield
one
log
decreas
viru
titer
result
least
three
assay
averag
activ
two
viru
strain
compar
student
test
statist
analys
perform
use
window
mac
graphpad
softwar
inc
la
jolla
ca
microsoft
excel
comparison
otherwis
detail
perform
student
twotail
test
assum
normal
distribut
equal
varianc
sophist
analys
perform
differ
observ
kolmogorovsmirnov
test
ks
test
normal
distribut
bartlett
test
equal
varianc
perform
applic
mdd
cytokin
valu
gross
lung
score
data
analyz
mannwhitney
pairwis
comparison
kruskalw
test
follow
dunn
multipl
comparison
test
applic
surviv
anim
includ
mdd
calcul
raw
surviv
number
compar
fisher
exact
test
survivor
curv
analysi
fig
done
use
kaplanmei
method
log
rank
test
analysi
reveal
signific
differ
among
treatment
group
pairwis
comparison
survivor
curv
analyz
gehanbreslowwilcoxon
test
rel
signific
adjust
bonferronicorrect
signific
threshold
number
treatment
comparison
made
differ
percent
weight
loss
test
oneway
anova
newmankeul
multipl
comparison
test
assum
equal
varianc
normal
distribut
lung
titer
data
perform
ks
test
normal
logtransform
valu
use
nonparametr
kruskalw
test
dunn
multipl
comparison
test
group
normal
distribut
oneway
anova
newmankeul
multipl
comparison
test
group
normal
distribut
ld
calcul
use
probit
analysi
statplu
mac
studi
conduct
accord
approv
institut
anim
care
use
committe
utah
state
univers
date
septemb
work
done
aaalacaccredit
laboratori
anim
research
center
utah
state
univers
us
govern
nation
institut
health
approv
renew
februari
assur
accord
nation
institut
health
guid
care
use
laboratori
anim
revis
special
provis
anim
lethal
comparison
allow
surviv
without
compassion
euthanasia
death
natur
occur
order
distinguish
weight
loss
mortal
experi
involv
infecti
sarscov
carri
laboratori
personnel
wore
complet
bodi
protect
cover
hepafilt
power
air
purifi
respir
